Clinical Trials Logo

Filter by:
NCT ID: NCT03843073 Recruiting - Clinical trials for Chronic Urinary Retention

Connected Catheter- Evaluation Study

Start date: February 2019
Phase: N/A
Study type: Interventional

The Connected Catheter is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization. It is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 7 days per Catheter

NCT ID: NCT03843060 Not yet recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

A Single Center Study in Healthy Volunteers to Assess the Pharmacokinetics of AZD9977 When Administered Alone and With Itraconazole

Start date: February 7, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.

NCT ID: NCT03843008 Not yet recruiting - Ischemic Stroke Clinical Trials

Melatonin in Acute Stroke

Start date: April 2019
Phase: N/A
Study type: Interventional

This study will measure Interleukin 6 (IL-6), a well-documented inflammatory biomarker that is increased in the acute phase of stroke, and to compare its levels after the administration of melatonin - a well-documented anti-inflammatory and anti-oxidant - that regulates circadian rhythm, which helps promote sleep.

NCT ID: NCT03842865 Available - Ovarian Cancer Clinical Trials

Expanded Access of Vigil in Solid Tumors

Start date: n/a
Phase:
Study type: Expanded Access

This is a multicenter, expanded access protocol of intradermal autologous Vigil immunotherapy. Subjects meeting expanded access eligibility criteria will receive a minimum of 1 immunotherapy dose of Vigil (1 x 10e4, 1 x 10e5, or 1 x 10e6 cells/injection), intradermally every 4 weeks as monotherapy.

NCT ID: NCT03842800 Recruiting - Clinical trials for Cognitive Impairment

Characterizing Clinical and Pharmacological Neuroimaging Biomarkers

Start date: April 1, 2013
Phase: N/A
Study type: Interventional

This study is part of a larger overall study that seeks to characterize clinical and pharmacological neuroimaging biomarkers. The purpose of this registered protocol is understand the effect of emotion on cognitions by specifically examining the effect of reward processing on working memory in patients with schizophrenia.

NCT ID: NCT03842709 Not yet recruiting - Chronic Pain Clinical Trials

Non-Opioid Pramipexole and Pain

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

The long-term goal of this proposal is to identify non-opioid drugs that harness endogenous anti-inflammatory mechanisms resulting in the suppression of proinflammatory cytokines such as IL-1ß providing a novel approach to treat chronic pain in people while lacking potential for addictive side effects. Specific Aim I: pramipexole blocks the activation of NLRP3 and consequent production and release of the proinflammatory cytokines IL-1ß, IL-6 and TNF-α, and increases production of the anti-inflammatory cytokine interleukin-10 (IL-10). The goal of Aim I (Phase I) experiments is to examine the specific anti-inflammatory mechanisms of pramipexole on PAMP, DAMP and opioid stimulated immune cells, THP-1 cells will be used. Specific Aim II: pramipexole treatment will provide therapeutic benefit to patients experiencing suboptimal pain relief from current standard therapy with concurrent reduction of TLR4-NLRP3-cytokine expression in peripheral blood mononuclear cells. The goal of Aim II (Phase II) will be to determine the therapeutic benefit of pramipexole for pain, which is a repurposing of this FDA-approved drug with a good safety profile. 1.2. Our overarching hypothesis is that pramipexole will control clinical pain by suppressing the activation of the TLR4-NLRP3-IL-1ß pathway and prevent IL-1ß release from peripheral immune cells. These findings have provided the current impetus to examine pain therapeutic drugs targeting immune-related factors either upstream or downstream of IL-1ß signaling.

NCT ID: NCT03842696 Not yet recruiting - Clinical trials for Myelodysplastic Syndromes

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Unrelated Donor Blood and Marrow Transplantation

Start date: March 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic HCT and determine whether the addition of Vorinostat to the standard preventive therapy (tacrolimus / methotrexate) will reduce the incidence of graft versus host disease (GVHD) following unrelated donor, myeloablative transplant in children, adolescents and young adults.

NCT ID: NCT03842670 Recruiting - Alcohol Dependence Clinical Trials

Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological Treatment for Alcohol Use Disorder

ABQ TREAT
Start date: November 14, 2018
Phase: N/A
Study type: Interventional

Alcohol Use Disorder (AUD) is a significant public health problem, with prevalence rates of 13.9% for current and 29.1% for lifetime diagnosis (Grant et al., 2015). AUD creates harm at the individual, familial, and societal level, with an estimated societal cost of $249 billion (Sacks et al., 2015) per year. The course of AUD typically is characterized by periods of relapse to problematic drinking (Maisto et al., 2014), signaling a need for better treatments and understanding of mechanisms of behavior change. The goal of this research is to conduct a randomized clinical trial with 140 participants who have an Alcohol Use Disorder (AUD). Each participant will complete behavioral assessments, self-report surveys and brain imaging before and after receiving psychotherapy treatment to change their drinking behaviors. Various aspects of behavior change will be looked at to better understand changes in brain function and emotional reactivity when someone changes their patterns of alcohol use. The two treatment used in this study have been found to be helpful in reducing alcohol use. Participants will be randomly assigned to either Mindfulness-Based Relapse Prevention (MBRP) or Cognitive Behavior Therapy (CBT) that will be completed in 12 weekly therapy sessions. It is anticipated that there will be numerous changes in brain function that are found when someone reduces or stops their alcohol use after the completion of 12 weeks of treatment.

NCT ID: NCT03842605 Completed - Hemophilia Clinical Trials

Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia

Start date: October 2012
Phase: N/A
Study type: Interventional

This is a research study of adults with hemophilia that have limitations in elbow joint motion that is the result of bleeding into the joint. People with hemophilia who have bleeding into their elbow joint may have limitations in elbow joint movement and pain in the joint. This research is being done to determine the effect a strength training program has on the amount of movement people with hemophilia and elbow joint disease have.

NCT ID: NCT03842501 Completed - Obesity Clinical Trials

Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity

Start date: July 1, 2018
Phase: Phase 3
Study type: Interventional

This randomized, double-blind placebo-controlled study was intended to measure the effects of the GWMP with Release supplement versus GWMP with placebo supplement in a representative group of obese subjects with or without diabetes at one outpatient medical practice.